BDUK Therapeutics develops a groundbreaking liver cancer therapy, utilizing pre-existing drugs combined into a novel and highly potent therapeutic product for an orphan drug disease with optimal G2M strategy. 
The current Liver cancer market size is $11 Bn, with no effective therapy (20% 5yr survival rate). The technology was developed in the Hebrew University and received the prestigious European Research Council (ERC) grant.


BDUK Therapeutics LTD.

Org chart

Teams

Offices